MSD’s pneumococcal vaccine hits ‘key endpoints’ in Phase III
Phase III trial evaluated use in infants 42-90 days old
Read More
Tag: Pneumococcal disease
Pfizer’s pneumococcal disease vaccine scores FDA priority review
Vaccine candidate previously scored fast-track and breakthrough therapy designations
Read More
FDA expands use of Pfizer’s Prevnar
US regulators have expanded the scope of Pfizer’s pneumococcal vaccine Prevnar 13, allowing its use in adults aged 18 to 49 years of age.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
